A chelation-assisted palladium-catalyzed C═Cbond cleavage of α, β-unsaturated ketone to form alkenyl nitrile in the presence of nitrile is disclosed on the basis of a formal group-exchange reaction formulated as C1═C2 + C3 → C1═C3 + C2, differing from normal alkene oxidative cleavage and metathesis type. The isolated key active Pd(II) complex as well as deuterium-labeled experiment revealed the necessity
α的螯合辅助钯催化的C = C键的断裂,β不饱和酮向腈的存在形式烯腈,公开了一种正式基交换反应的配制为C的基础上,1 = C 2 + C 3 →C 1 = C 3 + C 2,从正常烯烃氧化裂解和复分解型不同。分离出的关键活性 Pd(II) 配合物以及氘标记实验揭示了螯合基团的必要性,并提出了一条合理的催化途径。
KINASE INHIBITORS
申请人:Taunton, JR. John William
公开号:US20130035325A1
公开(公告)日:2013-02-07
Methods of inhibiting kinases using kinase inhibitors having olefin moieties are disclosed.
Lewis Acid Mediated Synthesis of 2-Alkenenitriles Using<i>C</i>,<i>N</i>-Bis(trimethylsilyl)ketenimine and Carbonyl Compounds
作者:Isamu Matsuda、Hisashi Okada、Yusuke Izumi
DOI:10.1246/bcsj.56.528
日期:1983.2
obtained in the condensation reaction of carbonylcompounds with C,N-bis(trimethylsilyl)ketenimine in the presence of Lewis acid. The combination of tris(trimethylsilyl)ketenimine and aldehydes results in the high E-selective formation of 2-trimethylsilyl-2-alkenenitriles. Among some Lewis acids, magnesium bromide gives the best E-selectivity in the formation of 2-trimethylsilyl-2-undecenenitrile. Stereospecific
在路易斯酸的存在下,羰基化合物与 C,N-双(三甲基甲硅烷基)烯酮亚胺的缩合反应得到 2-取代的 2-烯腈。三(三甲基甲硅烷基)烯酮亚胺和醛的组合导致 2-三甲基甲硅烷基-2-烯腈的高 E 选择性形成。在一些路易斯酸中,溴化镁在 2-三甲基甲硅烷基-2-十一烯腈的形成过程中具有最佳的 E 选择性。2-三甲基甲硅烷基-2-烯腈在氟化钾的甲醇水溶液中的立体特异性原脱甲硅烷基化实现了从醛到 (Z)-2-烯腈的新途径。
Applications of the Baylis–Hillman reaction 2: a simple stereoselective synthesis of (E)- and (Z)-trisubstituted alkenes
作者:Deevi Basavaiah、Pakala K. S. Sarma、Anagani K. D. Bhavani
DOI:10.1039/c39940001091
日期:——
Reaction of Grignard reagents with methyl 3-acetoxy-2-methylenealkanoates produces (2E)-2-substituted alk-2-enoates, whereas a similar reaction with 3-acetoxy-2-methylenealkanenitriles provides (2Z)-2-substituted alk-2-enenitriles in high (Z)-stereoselectivity.
申请人:BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
公开号:US20150361031A1
公开(公告)日:2015-12-17
Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.